Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which …

Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest …

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used …

Background: Monomethyl auristatin E (MMAE) has been used as a payload for several Food and Drug Administration (FDA) approved antibody-drug conjugates (ADCs). It is known that MMAE …

2022年7月5日 · Monomethyl auristatin (MMAE) is the most common ADC warhead conjugated to an expanding array of antibodies in clinical development for oncologic applications. In addition …

2025年2月5日 · Monomethyl auristatin E (MMAE) is a key payload in these ADCs due to its ability to disrupt microtubules and induce cell cycle arrest, making it an effective anti-cancer agent. …

2022年11月3日 · Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are identified as the best analogs of dolastatin 10, which bind to microtubules and prevent cell …

Tumor-directed antibodies and peptides conjugated to radiosensitizing monomethyl auristatin E (MMAE) specifically produce CD8 T cell dependent durable tumor control of irradiated tumors …

Herein, we propose tumor-specific monomethyl auristatin E (MMAE) prodrug nanoparticles for safe and effective chemotherapy. The cathepsin B-specific cleavable FRRG peptide and …

Mmae | C39H67N5O7 | CID 21976333 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity …